| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
85,817,000 |
| Market
Cap: |
234.28(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.69 - $3.12 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arbutus Biopharma is a clinical-stage biopharmaceutical company utilizing its virology expertise to develop therapeutics that target specific viral diseases. Co.'s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. Co.'s product pipeline consists of the following programs: GalNAc RNAi, which is a subcutaneously-delivered RNA interference therapeutic targeted to hepatocytes; Oral Capsid Inhibitor, which is a capsid inhibitor; Oral PD-L1 Inhibitor, which is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response; and Oral HBV RNA Destabilizer, which is is Co.'s oral HBV specific RNA destabilizer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
34,097 |
34,097 |
34,097 |
34,097 |
| Total Sell Value |
$78,849 |
$78,849 |
$78,849 |
$78,849 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
4 |
4 |
4 |
4 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Qvt Fund V Lp |
Director |
– • • |
2015-03-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
16,013,540 |
|
- |
|
| Roivant Sciences Ltd. |
10% Owner |
– – • |
2015-03-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,013,540 |
|
- |
|
| Jewell Donald Gordon |
Director |
– • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
484,665 |
|
- |
|
| Lutwyche Peter |
Sr VP, Pharmaceutical DevelopO |
• – – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
38,758 |
|
- |
|
| Brennan Paul A. |
Sr VP, Business DevelopOfficer |
• – – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,000 |
|
- |
|
| Phillips Peggy V |
Director |
– • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
- |
|
| Abrams Michael J. |
EVP & Chief Discovery OfficerO |
• – – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,875 |
|
- |
|
| Kisner Daniel L |
Director |
– • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,500 |
|
- |
|
| Karbe Frank |
Director |
– • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
| Murray Mark J. |
President & CEOOfficer |
• • – |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
64,961 |
|
- |
|
60 Records found
|
|
Page 3 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.37%) 
